REGN vs VRCA · P/E 14, rev $4.29B vs rev $7.6M
Regeneron Pharmaceuticals Inc (REGN) versus Verrica Pharmaceuticals Inc (VRCA) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Verrica Pharmaceuticals Inc (VRCA) is a biotechnology company listed on US.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported VRCA revenue for 2024-12-31 was $7.6M. Net income was -$76.6M. Revenue was up 47.7% from 2023-12-31 to 2024-12-31. VRCA currently screens at market cap $79.7M.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. VRCA currently screens at market cap $79.7M.
Not investment advice. Open the REGN and VRCA stock pages for the full models.
Not investment advice.